201 related articles for article (PubMed ID: 37200859)
21. Lipid Nanoparticle Delivery of Fas Plasmid Restores Fas Expression to Suppress Melanoma Growth
Al Subeh ZY; Poschel DB; Redd PS; Klement JD; Merting AD; Yang D; Mehta M; Shi H; Colson YL; Oberlies NH; Pearce CJ; Colby AH; Grinstaff MW; Liu K
ACS Nano; 2022 Aug; 16(8):12695-12710. PubMed ID: 35939651
[TBL] [Abstract][Full Text] [Related]
22. A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq.
Boroughs AC; Larson RC; Marjanovic ND; Gosik K; Castano AP; Porter CBM; Lorrey SJ; Ashenberg O; Jerby L; Hofree M; Smith-Rosario G; Morris R; Gould J; Riley LS; Berger TR; Riesenfeld SJ; Rozenblatt-Rosen O; Choi BD; Regev A; Maus MV
Mol Ther; 2020 Dec; 28(12):2577-2592. PubMed ID: 32755564
[TBL] [Abstract][Full Text] [Related]
23. Kinetics of expression and subset distribution of the TNF superfamily members CD40 ligand and Fas ligand on T lymphocytes in cattle.
Hirano A; Brown WC; Trigona W; Tuo W; Estes DM
Vet Immunol Immunopathol; 1998 Feb; 61(2-4):251-63. PubMed ID: 9613439
[TBL] [Abstract][Full Text] [Related]
24. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs.
Hauer J; Püschner S; Ramakrishnan P; Simon U; Bongers M; Federle C; Engelmann H
Proc Natl Acad Sci U S A; 2005 Feb; 102(8):2874-9. PubMed ID: 15708970
[TBL] [Abstract][Full Text] [Related]
25. Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer.
Priceman SJ; Gerdts EA; Tilakawardane D; Kennewick KT; Murad JP; Park AK; Jeang B; Yamaguchi Y; Yang X; Urak R; Weng L; Chang WC; Wright S; Pal S; Reiter RE; Wu AM; Brown CE; Forman SJ
Oncoimmunology; 2018; 7(2):e1380764. PubMed ID: 29308300
[TBL] [Abstract][Full Text] [Related]
26. Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40.
Foster AE; Mahendravada A; Shinners NP; Chang WC; Crisostomo J; Lu A; Khalil M; Morschl E; Shaw JL; Saha S; Duong MT; Collinson-Pautz MR; Torres DL; Rodriguez T; Pentcheva-Hoang T; Bayle JH; Slawin KM; Spencer DM
Mol Ther; 2017 Sep; 25(9):2176-2188. PubMed ID: 28697888
[TBL] [Abstract][Full Text] [Related]
27. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2
Dai Q; Han P; Qi X; Li F; Li M; Fan L; Zhang H; Zhang X; Yang X
Front Immunol; 2020; 11():539654. PubMed ID: 33281809
[TBL] [Abstract][Full Text] [Related]
28. The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis.
Bugajska U; Georgopoulos NT; Southgate J; Johnson PW; Graber P; Gordon J; Selby PJ; Trejdosiewicz LK
J Natl Cancer Inst; 2002 Sep; 94(18):1381-95. PubMed ID: 12237284
[TBL] [Abstract][Full Text] [Related]
29. CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.
Kuhn NF; Purdon TJ; van Leeuwen DG; Lopez AV; Curran KJ; Daniyan AF; Brentjens RJ
Cancer Cell; 2019 Mar; 35(3):473-488.e6. PubMed ID: 30889381
[TBL] [Abstract][Full Text] [Related]
30. CD40 activation-induced, Fas-dependent apoptosis and NF-kappaB/AP-1 signaling in human intrahepatic biliary epithelial cells.
Afford SC; Ahmed-Choudhury J; Randhawa S; Russell C; Youster J; Crosby HA; Eliopoulos A; Hubscher SG; Young LS; Adams DH
FASEB J; 2001 Nov; 15(13):2345-54. PubMed ID: 11689460
[TBL] [Abstract][Full Text] [Related]
31. CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit.
Yi F; Cohen T; Zimmerman N; Dündar F; Zumbo P; Eltilib R; Brophy EJ; Arkin H; Feucht J; Gormally MV; Hackett CS; Kropp KN; Etxeberria I; Chandran SS; Park JH; Hsu KC; Sadelain M; Betel D; Klebanoff CA
bioRxiv; 2024 Mar; ():. PubMed ID: 38464085
[TBL] [Abstract][Full Text] [Related]
32. A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy.
Oda SK; Anderson KG; Ravikumar P; Bonson P; Garcia NM; Jenkins CM; Zhuang S; Daman AW; Chiu EY; Bates BM; Greenberg PD
J Exp Med; 2020 Dec; 217(12):. PubMed ID: 32860705
[TBL] [Abstract][Full Text] [Related]
33. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
34. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.
Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK
Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655
[TBL] [Abstract][Full Text] [Related]
35. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
36. A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy.
Upadhyay R; Boiarsky JA; Pantsulaia G; Svensson-Arvelund J; Lin MJ; Wroblewska A; Bhalla S; Scholler N; Bot A; Rossi JM; Sadek N; Parekh S; Lagana A; Baccarini A; Merad M; Brown BD; Brody JD
Cancer Discov; 2021 Mar; 11(3):599-613. PubMed ID: 33334730
[TBL] [Abstract][Full Text] [Related]
37. Road testing new CAR design strategies in multiple myeloma.
Rana PS; Murphy EV; Kort J; Driscoll JJ
Front Immunol; 2022; 13():957157. PubMed ID: 36016950
[TBL] [Abstract][Full Text] [Related]
38. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR
Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370
[TBL] [Abstract][Full Text] [Related]
39. Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation.
Halim L; Das KK; Larcombe-Young D; Ajina A; Candelli A; Benjamin R; Dillon R; Davies DM; Maher J
Front Immunol; 2022; 13():836549. PubMed ID: 35222427
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
